Business Context and Reporting Period
This Form 8-K was filed by Pro-Pharmaceuticals, Inc. (noted as Galectin Therapeutics Inc. in metadata) on June 19, 2007. The report details the entry into a Material Definitive Agreement for a private placement financing.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $2,712,749
- Shares Issued: 4,173,460 shares of Common Stock
- Offering Price: $0.65 per share
- Warrants Issued: Warrants to purchase 4,173,460 shares (1:1 ratio)
- Warrant Exercise Price: $0.80 per share
- Warrant Term: 7 years (exercisable after 6 months)
The filing does not provide data on revenue, profit, cash flow, margins, or existing debt levels.
Material Changes and Transaction Terms
The company entered into a Securities Purchase Agreement with institutional investors. Key terms include:
- Anti-Dilution Provisions: Purchasers are entitled to additional shares if the company issues stock below $0.65 prior to the six-month anniversary of the resale registration statement. Warrant exercise prices are subject to adjustment if stock is issued below $0.80.
- Ownership Cap: If adjustments cause total issuance to exceed 19.99% of outstanding shares, stockholder approval is required.
- Future Participation: Purchasers have the right to participate in future financings for 18 months following the effective date of the resale registration statement.
- Listing Requirement: Closing is contingent upon approval of listing the shares and warrant shares on the American Stock Exchange.
Outlook, Risks, and Contingencies
The transaction is subject to customary closing conditions, including the listing approval mentioned above. The securities are being sold under Section 4(2) of the Securities Act of 1933 to accredited investors and qualified institutional buyers. Management commentary is limited to the announcement of the financing agreement.
Investor Verification Checklist
- Verify the final closing date and confirmation of gross proceeds received.
- Confirm the approval of the listing on the American Stock Exchange.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific conditions precedent.
- Monitor future filings for the effective date of the resale registration statement to determine the start of the warrant exercise period and future financing participation rights.
- Check for any subsequent issuances of stock below $0.65 that would trigger anti-dilution adjustments.